Skip to content

Combined therapy with intronasal corticosteroids for simple asthma and observation of its curative effect

Combined therapy with intronasal corticosteroids for simple asthma and observation of its curative effect

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12003516
Enrollment
Unknown
Registered
2012-08-13
Start date
2012-08-13
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Asthma treatment group:Budisonide nasal spray and Budisonide/formoteral
Asthma control group:Placebo and Budisonide/formoteral

Sponsors

Guangzhou Institute of Respiratory Diseases
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. aged 18~60 mild-to-moderate simple asthma; 2. after nasal examination (nasal lavage counting EOS>2.58/*200) was included in the research; 3. determination of pulmonary function FEV1 %Pred (forced expiratory volume in 1 second of expected value percentage)70% or higher; 4. X-ray films has no obvious abnormalities; 5. Participants must be willing to participate in the study and to comply with the requirements of the study, understand and observe and comply with the corresponding inspection, comply with the dosage plan, follow-up, and voluntarily signing a written informed consent.

Exclusion criteria

Exclusion criteria: 1. associated with COPD, interstitial pneumonia, other types of chronic respiratory system disease etc; with other serious systematic disease (such as cardiovascular, metabolic, immune, neural, urinary and blood, etc.); 2. has a history of the nasal tumors, trauma, nasal septum deviation obviously, specialist sinusitis, allergic rhinitis has been diagnosed; 3. upper or lower respiratory tract infection within recent four weeks; 4. the body temperature is more than 37.5 ? or abnormal blood test(white blood cell count > 10x10*9/L or <4x10*9/L); 5. history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study; 6. smoking patients (or smoking cessation less than four weeks); 7. during pregnancy, lactation women; 8. taking part in other drug clinical trial project; 9. can not cooperate with related inspection or for other reasons.

Design outcomes

Primary

MeasureTime frame
Eosinophil in nasal lavage;Eosinophil in induced sputum;FeNO;branchial provocation test;Histamine nasal provocation test;Skin prick test;Eosinophil count in blood;Total IgE in serum;

Countries

China

Contacts

Public ContactZhong Nanshan
nanshan@vip.163.com+86 13609003622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026